Mostrar el registro sencillo del ítem

dc.contributor.authorKovar, Heinrich
dc.contributor.authorAlonso, Javier 
dc.contributor.authorAman, Pierre
dc.contributor.authorAryee, Dave N T
dc.contributor.authorBan, Jozef
dc.contributor.authorBurchill, Sue A
dc.contributor.authorBurdach, Stefan
dc.contributor.authorDe Alava, Enrique
dc.contributor.authorDelattre, Olivier
dc.contributor.authorDirksen, Uta
dc.contributor.authorFourtouna, Argyro
dc.contributor.authorFulda, Simone
dc.contributor.authorHelman, Lee J
dc.contributor.authorHerrero-Martin, David
dc.contributor.authorHogendoorn, Pancras C W
dc.contributor.authorKontny, Udo
dc.contributor.authorLawlor, Elizabeth R
dc.contributor.authorLessnick, Stephen L
dc.contributor.authorLlombart-Bosch, Antonio
dc.contributor.authorMetzler, Markus
dc.contributor.authorMoriggl, Richard
dc.contributor.authorNiedan, Stephan
dc.contributor.authorPotratz, Jenny
dc.contributor.authorRedini, Françoise
dc.contributor.authorRichter, Günther H S
dc.contributor.authorRiedmann, Lucia T
dc.contributor.authorRossig, Claudia
dc.contributor.authorSchäfer, Beat W
dc.contributor.authorSchwentner, Raphaela
dc.contributor.authorScotlandi, Katia
dc.contributor.authorSorensen, Poul H
dc.contributor.authorStaege, Martin S
dc.contributor.authorTirode, Franck
dc.contributor.authorToretsky, Jeffrey
dc.contributor.authorVentura, Selena
dc.contributor.authorEggert, Angelika
dc.contributor.authorLadenstein, Ruth
dc.date.accessioned2019-01-10T16:07:17Z
dc.date.available2019-01-10T16:07:17Z
dc.date.issued2012-05
dc.identifier.citationFront Oncol. 2012;2:54es_ES
dc.identifier.issn2234-943Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6991
dc.description.abstractThe European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEwing sarcomaes_ES
dc.subjectAnimal modelses_ES
dc.subjectBiomarkerses_ES
dc.subjectDrug screenes_ES
dc.subjectEpigeneticses_ES
dc.subjectGenomicses_ES
dc.subjectPrognosises_ES
dc.subjectSarcomagenesises_ES
dc.titleThe first European interdisciplinary ewing sarcoma research summites_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-4.0 Internacional*
dc.identifier.pubmedID22662320es_ES
dc.format.volume2es_ES
dc.format.page54es_ES
dc.identifier.doi10.3389/fonc.2012.00054es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2234-943Xes_ES
dc.relation.publisherversionhttps://www.doi.org/10.3389/fonc.2012.00054es_ES
dc.identifier.journalFrontiers in oncologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-4.0 Internacional